Annual Operating Expenses
$11.37 M
-$6.88 M-37.70%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual total operating expenses is $11.37 million, with the most recent change of -$6.88 million (-37.70%) on March 1, 2024.
- During the last 3 years, GRCE annual operating expenses has risen by +$531.00 thousand (+4.90%).
- GRCE annual operating expenses is now -66.23% below its all-time high of $33.66 million, reached on March 1, 2019.
Performance
GRCE Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$4.83 M
-$132.00 K-2.66%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly total operating expenses is $4.83 million, with the most recent change of -$132.00 thousand (-2.66%) on September 1, 2024.
- Over the past year, GRCE quarterly operating expenses has increased by +$1.79 million (+58.76%).
- GRCE quarterly operating expenses is now -55.49% below its all-time high of $10.85 million, reached on March 1, 2019.
Performance
GRCE Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
GRCE Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -37.7% | +58.8% |
| 3 y3 years | +4.9% | -5.4% |
| 5 y5 years | -66.2% | -22.8% |
GRCE Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -37.7% | +4.9% | -5.4% | +130.9% |
| 5 y | 5-year | -66.2% | +4.9% | -21.4% | +146.2% |
| alltime | all time | -66.2% | +638.9% | -55.5% | +2461.5% |
Grace Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.83 M(-2.7%) |
| Jun 2024 | - | $4.96 M(+52.1%) |
| Mar 2024 | $11.37 M(-37.7%) | $3.26 M(+7.2%) |
| Dec 2023 | - | $3.04 M(+45.5%) |
| Sep 2023 | - | $2.09 M(-29.5%) |
| Jun 2023 | - | $2.97 M(-28.7%) |
| Mar 2023 | $18.25 M(+19.0%) | $4.17 M(-1.9%) |
| Dec 2022 | - | $4.25 M(-16.9%) |
| Sep 2022 | - | $5.11 M(+8.0%) |
| Jun 2022 | - | $4.73 M(+7.4%) |
| Mar 2022 | $15.34 M(+41.6%) | $4.40 M(+4.2%) |
| Dec 2021 | - | $4.22 M(+18.4%) |
| Sep 2021 | - | $3.57 M(+13.4%) |
| Jun 2021 | - | $3.15 M(+60.3%) |
| Mar 2021 | $10.84 M(-55.7%) | $1.96 M(-2.3%) |
| Dec 2020 | - | $2.01 M(-26.8%) |
| Sep 2020 | - | $2.74 M(-33.4%) |
| Jun 2020 | - | $4.12 M(+2.2%) |
| Mar 2020 | $24.44 M(-27.4%) | $4.03 M(-34.4%) |
| Dec 2019 | - | $6.15 M(-1.7%) |
| Sep 2019 | - | $6.25 M(-21.9%) |
| Jun 2019 | - | $8.01 M(-26.2%) |
| Mar 2019 | $33.66 M(+120.7%) | $10.85 M(+38.0%) |
| Dec 2018 | - | $7.86 M(-2.7%) |
| Sep 2018 | - | $8.08 M(+7.1%) |
| Jun 2018 | - | $7.54 M(+38.6%) |
| Mar 2018 | $15.25 M(+81.4%) | $5.44 M(+32.9%) |
| Dec 2017 | - | $4.10 M(+15.9%) |
| Sep 2017 | - | $3.53 M(+64.2%) |
| Jun 2017 | - | $2.15 M(+15.1%) |
| Mar 2017 | $8.41 M | - |
| Date | Annual | Quarterly |
|---|---|---|
| Nov 2016 | - | $1.87 M(-0.1%) |
| Aug 2016 | - | $1.87 M(-17.5%) |
| May 2016 | - | $2.27 M(+46.4%) |
| Feb 2016 | $7.09 M(-28.4%) | $1.55 M(-21.4%) |
| Nov 2015 | - | $1.97 M(+20.6%) |
| Aug 2015 | - | $1.63 M(-22.2%) |
| May 2015 | - | $2.10 M(+25.5%) |
| Feb 2015 | $9.91 M(+0.1%) | $1.67 M(-35.4%) |
| Nov 2014 | - | $2.59 M(-18.5%) |
| Aug 2014 | - | $3.18 M(+15.0%) |
| May 2014 | - | $2.77 M(+61.1%) |
| Feb 2014 | $9.89 M(+38.8%) | $1.72 M(-45.2%) |
| Nov 2013 | - | $3.13 M(-2.1%) |
| Aug 2013 | - | $3.20 M(+66.4%) |
| May 2013 | - | $1.92 M(+6.9%) |
| Feb 2013 | $7.13 M(+8.7%) | $1.80 M(-1.2%) |
| Nov 2012 | - | $1.82 M(-2.5%) |
| Aug 2012 | - | $1.87 M(+18.2%) |
| May 2012 | - | $1.58 M(-3.8%) |
| Feb 2012 | $6.56 M(+103.7%) | $1.64 M(-23.4%) |
| Nov 2011 | - | $2.14 M(+19.3%) |
| Aug 2011 | - | $1.80 M(+59.3%) |
| May 2011 | - | $1.13 M(-9.6%) |
| Feb 2011 | $3.22 M(+109.2%) | $1.25 M(+61.6%) |
| Nov 2010 | - | $772.20 K(+20.3%) |
| Aug 2010 | - | $641.70 K(+25.2%) |
| May 2010 | - | $512.60 K(+22.1%) |
| Feb 2010 | $1.54 M | $419.80 K(+10.9%) |
| Nov 2009 | - | $378.60 K(-16.1%) |
| Aug 2009 | - | $451.30 K(+70.6%) |
| May 2009 | - | $264.50 K(+40.2%) |
| Nov 2008 | - | $188.60 K |
FAQ
- What is Grace Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Grace Therapeutics?
- What is Grace Therapeutics annual operating expenses year-on-year change?
- What is Grace Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Grace Therapeutics?
- What is Grace Therapeutics quarterly operating expenses year-on-year change?
What is Grace Therapeutics annual total operating expenses?
The current annual operating expenses of GRCE is $11.37 M
What is the all time high annual operating expenses for Grace Therapeutics?
Grace Therapeutics all-time high annual total operating expenses is $33.66 M
What is Grace Therapeutics annual operating expenses year-on-year change?
Over the past year, GRCE annual total operating expenses has changed by -$6.88 M (-37.70%)
What is Grace Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of GRCE is $4.83 M
What is the all time high quarterly operating expenses for Grace Therapeutics?
Grace Therapeutics all-time high quarterly total operating expenses is $10.85 M
What is Grace Therapeutics quarterly operating expenses year-on-year change?
Over the past year, GRCE quarterly total operating expenses has changed by +$1.79 M (+58.76%)